Effect of aerosol inhalation of Salbutamol combined with Suhuang Zhike Capsules in acute exacerbation of chronic obstructive pulmonary disease
YANG Xiao-qing CHEN Guang CHEN Xiao-yun LIU Hou-qiang
Department of Respiratory Medicine,Yunfu Hospital of Traditional Chinese Medicine,the Second Affiliated Hospital of Guangdong Pharmaceutical University,Guangdong Province,Yunfu 527300,China
Abstract:Objective To explore the effect of aerosol inhalation of Salbutamol combined with Suhuang Zhike Capsules in acute exacerbation of chronic obstructive pulmonary disease (AECOPD).Methods A total of 128 cases with AECOPD treated in our hospital from April 2016 to April 2018 were selected as the subjects,and divided into observation group and control group,with 64 cases in each group.The control group was treated with Salbutamol inhalation,and the observation group was treated with Suhuang Zhike Capsules on the basis of the control group.The curative effect,improvement of pulmonary function and incidence of adverse reactions between the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group (P<0.05).The values of forced expiratory volume in one second(FEV1),FEV1/FVC and peak expiratory flowrate(PEF)in the observation group were higher than those in the control group (P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Salbutamol atomization inhalation combined with Suhuang Zhike Capsules in the treatment of AECOPD can achieve significant effect,improve the pulmonary function.It has good safety and is worthy of clinical application.
Zeki AA,Jarjour NN.The asthma-chronic obstructive pulmonary disease overlap syndrome:a new take on an old concept[J].Ann Am Thorac Soc,2016,13(9):1440-1442.
赵翔宇.硫酸沙丁胺醇与噻托溴铵联合治疗对AECOPD患者 CysC、hs-CRP和 PA 的影响[J].现代医学,2016,21(4):479-483.
[13]
Cosío BG,Shafiek H,Iglesias A,et al.Oral low-dose theophylline on top of inhaled fluticasone-salmeterol does not reduce exacerbations in patients with severe COPD:a pilot clinical trial[J].Chest,2016,150(1):123-130.